Immunocore Announces Appointment of Eva-Lotta Allan to the Board
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Immunocore Limited announced the appointment of Eva-Lotta Allan to the Board as Chief Business Officer. This is a new position, which has been created to strengthen the company’s management team as Immunocore continues to expand its operations. Ms Allan will join Immunocore on 7 May 2013.
Immunocore has created a world-leading T cell receptor technology which exploits the power of the body’s own immune system to find and kill diseased cells. The company is developing a portfolio of products from the platform, called ImmTACs, for the treatment of cancer, chronic infectious disease and diabetes. The most advanced ImmTAC drug, IMCgp100 for the treatment of melanoma, is currently in clinical trials in the UK and USA.
Eva-Lotta Allan brings over two decades of business development experience from the biotechnology and life science industry and joins from Ablynx NV, where she served as Chief Business Officer since 2006. She was a key contributor to Ablynx’s transformation from a small private platform company to a significant public biotechnology company with an impressive pipeline and partnerships. In her role as Ablynx’s CBO, she closed a number of deals of significant value, with premier pharmaceutical companies bringing in over €160 million in non-dilutive cash to the company. Prior to Ablynx, Ms Allan was Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals. She received her degree in microbiology from the University of Stockholm.
James Noble, Immunocore’s Chief Executive Officer, said: “I am pleased to welcome Eva-Lotta to our senior Management team and Board of Directors at this critical point for Immunocore as we expand and develop our pipeline of products. She brings with her a wealth of knowledge and experience in business development.”
Eva-Lotta Allan commented on her appointment: “I am delighted to be joining Immunocore at this exciting time. I have been impressed by the quality of the science and unique and broad application of ImmTACs in cancer. I look forward to working with the Immunocore team and to establishing strategically important collaborations.”
Immunocore has created a world-leading T cell receptor technology which exploits the power of the body’s own immune system to find and kill diseased cells. The company is developing a portfolio of products from the platform, called ImmTACs, for the treatment of cancer, chronic infectious disease and diabetes. The most advanced ImmTAC drug, IMCgp100 for the treatment of melanoma, is currently in clinical trials in the UK and USA.
Eva-Lotta Allan brings over two decades of business development experience from the biotechnology and life science industry and joins from Ablynx NV, where she served as Chief Business Officer since 2006. She was a key contributor to Ablynx’s transformation from a small private platform company to a significant public biotechnology company with an impressive pipeline and partnerships. In her role as Ablynx’s CBO, she closed a number of deals of significant value, with premier pharmaceutical companies bringing in over €160 million in non-dilutive cash to the company. Prior to Ablynx, Ms Allan was Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals. She received her degree in microbiology from the University of Stockholm.
James Noble, Immunocore’s Chief Executive Officer, said: “I am pleased to welcome Eva-Lotta to our senior Management team and Board of Directors at this critical point for Immunocore as we expand and develop our pipeline of products. She brings with her a wealth of knowledge and experience in business development.”
Eva-Lotta Allan commented on her appointment: “I am delighted to be joining Immunocore at this exciting time. I have been impressed by the quality of the science and unique and broad application of ImmTACs in cancer. I look forward to working with the Immunocore team and to establishing strategically important collaborations.”
